Streptococcus agalactiae or group B, is the mayor causing agent of early onset neonatal sepsis. Although mayor prevention strategies have been made, the expected effectiveness hasn't been achieved. That's why efforts have been made to develop a vaccine that can prevent most of the diseases these bacteria can produce, including early and late onset neonatal sepsis. These way, actual antibiotic prophylaxis limitations can be avoided. Attempts include the utilization of Streptococcus group B polysaccharides in their puré state or combined with proteins as tetanic toxoid. Specific capsule proteins have been used also because of their po-tential effectiveness as inmunogenic factors. Overall vaccines conjugated ones are the most studied, having completed phase II clinical triáis in healthy adults and pregnant women. Neonatal sepsis is a severe compli-cation that has not been controlled yet, so the creation of a vaccine against this pathogen would be of great impact in public health. We introduce now the different developed vaccines and their state of progress.
Campodónico O, L., Doren V, A., Cruz O, M., & Abarzúa C, F. (2009). PROFILAXIS DE SEPSIS NEONATAL PRECOZ POR STREPTOCOCCUS AGALACTIAE (GRUPO B) BASADA EN VACUNAS: REVISIÓN DE LA LITERATURA. Revista Chilena de Obstetricia y Ginecología, 73(6). https://doi.org/10.4067/s0717-75262008000600011